AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
At close
$1.75
−$0.08 (−4.12%) Close
Prev closePrevC$1.82
OpenOpen$1.78
Day highHigh$1.78
Day lowLow$1.71
VolumeVol30,178
Avg volAvgVol5,251,430
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$595.72M
P/E ratio
-7.93
FY Revenue
$5.37M
EPS
-0.22
Gross Margin
100.00%
Sector
Healthcare
AI report sections
BULLISH
OCGN
Ocugen, Inc.
Ocugen’s shares show notable upward momentum over the past six months, supported by multiple bullish technical signals near the middle-to-upper portion of the 52-week range. At the same time, fundamentals remain deeply loss-making with heavily negative margins and free cash flow, indicating reliance on external financing. Elevated short interest and a high days-to-cover figure point to ongoing skepticism and potential volatility despite a generally constructive recent news backdrop.
AI summarized at 1:57 PM ET, 2026-01-12
AI summary scores
INTRADAY:63SWING:68LONG:34
Volume vs average
Intraday (cumulative)
+86% (Above avg)
Vol/Avg: 1.86×
RSI
71.87(Overbought)
Overbought (>70)
0255075100
MACD momentum
Intraday
+0.00 (Strong)
MACD: 0.01 Signal: 0.00
Short-Term
+0.05 (Strong)
MACD: 0.07 Signal: 0.02
Long-Term
+0.04 (Strong)
MACD: 0.09 Signal: 0.05
Intraday trend score
71.28
LOW46.28HIGH75.78
Latest news
OCGN•12 articles•Positive: 7Neutral: 3Negative: 2
PositiveGlobeNewswire Inc.• Na
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
Ocugen announced a webcast on January 15, 2026 to discuss Phase 2 clinical trial data from the OCU410 ArMaDa trial, featuring leading ophthalmologists and company executives. The presentation will cover one-year follow-up data from the first half of patients treated with the modifier gene therapy for blindness diseases.
The company is presenting clinical trial data from a Phase 2 study, indicating progress in its gene therapy pipeline. The webcast featuring prominent clinical investigators and discussion of one-year patient data suggests meaningful results worth presenting to stakeholders and the investment community.
NeutralGlobeNewswire Inc.• Delveinsight
Gene Therapy for Ocular Rare Disease Market to Exhibit Phenomenal Growth During the Forecast Period (2025–2034) Due to Expanding Pipeline and Clinical Trial Activities | DelveInsight
The gene therapy market for ocular rare diseases is expanding rapidly, with breakthrough viral vector technologies enabling one-time, disease-modifying treatments for inherited retinal disorders. Multiple emerging therapies are expected to transform treatment options for previously untreatable eye conditions.
Developing investigational gene therapy OCU400 for inherited retinal diseases with potential future market impact
PositiveThe Motley Fool• Eric Volkman
Why Ocugen Stock Zoomed 12% Higher Today
Ocugen announced a licensing agreement with Kwangdong Pharmaceutical for OCU400, an investigational drug targeting retinitis pigmentosa, potentially earning up to $7.5 million upfront and future royalties of 25% on net sales in South Korea.
OCGNlicensingbiotecheye disordersretinitis pigmentosadrug development
Sentiment note
Stock rose 12% following the licensing deal, with potential for significant future revenue from drug sales and royalties in South Korea
NeutralGlobeNewswire Inc.• Tiffany Hamilton
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
Ocugen, a biotechnology company focused on gene therapies for blindness diseases, closed a $20 million registered direct offering with Janus Henderson Investors, selling 20 million shares and warrants at $1.00 per share.
The company is raising capital to extend its cash runway into 2026/2027, indicating a strategic financial move to support ongoing research and development
NeutralGlobeNewswire Inc.• Tiffany Hamilton
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
Ocugen has entered into a securities purchase agreement with Janus Henderson Investors to sell 20 million shares of common stock and warrants at $1.00 per share, expecting to raise approximately $20 million in gross proceeds.
The company is raising capital through a registered direct offering, which is a standard financing method for biotechnology firms to fund research and development
PositiveGlobeNewswire Inc.• Delveinsight
AAV for the Hereditary Retinal Diseases Clinical Trial Pipeline Analysis Demonstrates 70+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
A comprehensive analysis reveals over 70 companies developing AAV gene therapies for hereditary retinal diseases, offering potential transformative treatments for vision restoration through advanced gene therapy techniques.
Received rare pediatric disease designation for OCU410ST, indicating promising progress in treating retinal diseases
NegativeBenzinga• Henry Khederian
Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On?
Ocugen's shares are trading lower after the company announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics in an all-stock deal.
OCGNCARMOcugenmergerCarisma Therapeutics
Sentiment note
Ocugen's shares are trading lower following the announcement of the merger agreement, indicating that investors view the deal negatively.
PositiveGlobeNewswire Inc.• N/A
Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results
Ocugen, a biotechnology company focused on gene therapies for blindness diseases, will host a conference call to discuss its Q1 2025 financial results and provide a business update.
The article announces that Ocugen will host a conference call to discuss its financial results and provide a business update, which suggests the company is making progress in its operations and development of gene therapies for blindness diseases.
NegativeGlobeNewswire Inc.• Grabar Law Office
Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your Behalf
Grabar Law Office is investigating claims on behalf of long-term shareholders of Driven Brands, Mercury Systems, MGP Ingredients, and Ocugen, alleging that certain officers and directors of these companies have breached their fiduciary duties.
The article states that a securities fraud class action complaint alleges that Ocugen, through certain of its officers and directors, made materially false and/or misleading statements and/or failed to disclose that the company's financial statements were materially misstated and it did not have adequate internal controls.
PositiveGlobeNewswire Inc.• Delveinsight
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight
The cell and gene therapies in rare disorders market is expected to grow significantly by 2034, driven by an increase in approvals and adoption of these treatments, ability to treat a broad array of conditions, and rising prevalence of rare disorders.
RGNXSGMORAREPFEcell and gene therapiesrare disordersmarket growthtreatment landscape
Sentiment note
Ocugen is developing OCU400, a gene therapy for inherited retinal disorders, which is in clinical development.
PositiveGlobeNewswire Inc.• N/A
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Ocugen, a biotechnology company, will host a conference call on March 5, 2025, to discuss its fourth quarter and full-year 2024 financial results and provide a business update.
The article announces that Ocugen will host a conference call to discuss its financial results and provide a business update, which suggests the company is actively engaged in its operations and providing updates to investors.
PositiveGlobeNewswire Inc.• N/A
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
Ocugen, Inc. announced that the FDA has reviewed and approved its Investigational New Drug (IND) application for OCU500, an inhaled mucosal vaccine for COVID-19. The company will collaborate with NIAID to conduct a Phase 1 clinical trial to assess the safety, tolerability, and immunogenicity of the vaccine.
The article highlights Ocugen's progress in developing a novel COVID-19 vaccine candidate, OCU500, which has received FDA approval to initiate a Phase 1 clinical trial. This is a significant milestone for the company and suggests its vaccine technology has potential.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
